# Glioblastoma Aspirin is unusually interesting in **glioblastoma**. This is not because it has strong clinical trial evidence. It does not. The reason is different. Glioblastoma exposes several aspirin-sensitive vulnerabilities at once, including **cancer stem cells**, **temozolomide resistance**, **angiogenesis**, and **Wnt / β-catenin** signalling. The whole field still runs into one hard limit: **blood-brain barrier penetration**. That is the main reason this page remains largely preclinical. Even so, the mechanism work is deep enough that glioblastoma deserves its own place in the aspirin section. [Read the stem-cell paper](https://pubmed.ncbi.nlm.nih.gov/30701538/) ### Overview Glioblastoma multiforme, or **GBM**, is the most aggressive primary brain tumour in adults. Despite surgery, radiotherapy, and **temozolomide**, recurrence is almost universal. A major reason is the persistence of **glioblastoma stem cells**, or **GSCs**, which are more resistant to treatment and can repopulate the tumour after therapy. Aspirin is relevant here because it appears to hit several of these recurrence pathways directly. It has shown anti-stem-cell effects, sensitisation to **temozolomide** and **bevacizumab**, and suppression of glioblastoma proliferation and invasion through more than one pathway. [Read the angiogenesis paper](https://www.sciencedirect.com/science/article/abs/pii/S1878875018318631) ### Key human data #### Prevention and epidemiology This is the only part of the glioblastoma story with a real human population signal. * **AACR 2016 report:** Regular aspirin use was associated with about **34% lower glioma risk**, with a duration-response pattern. [Read the coverage](https://www.livescience.com/54471-aspirin-linked-to-lower-brain-cancer-risk.html) * **Secondary analysis of cardiovascular trials:** Long-term low-dose aspirin was associated with lower risk of death from **primary brain tumours** within the first 10 years of use, with a reported **HR of 0.31**. [Read the paper](https://pmc.ncbi.nlm.nih.gov/articles/PMC3619088/) These findings are important, but they are not enough to support aspirin as a glioma-prevention standard. They are best read as supportive epidemiology rather than settled practice. #### Post-diagnosis data This remains the weak area. There is **no human randomised adjuvant trial** showing that standard oral aspirin improves survival in glioblastoma. The clinically interesting work is still mechanistic and preclinical. ### Mechanistic relevance #### Cancer stem-cell targeting This is one of the strongest reasons the page matters. Aspirin has shown direct effects on **glioblastoma stem cells**. In these models, aspirin induced **G1 cell-cycle arrest** and increased **p21** and **p27**, while reducing **Cyclin D1** and **Rb1 phosphorylation**. [Read the stem-cell paper](https://pubmed.ncbi.nlm.nih.gov/30701538/) More importantly, aspirin suppressed several core stem-cell maintenance proteins at the same time: * **Notch1** * **Sox2** * **Stat3** * **Survivin** That combination matters because these proteins help maintain self-renewal, recurrence risk, and treatment resistance in GBM. The study also suggested this effect was at least partly **COX-independent**, because adding back **PGE2** did not reverse it. [Read the stem-cell paper](https://pubmed.ncbi.nlm.nih.gov/30701538/) #### Temozolomide sensitisation through SHH / GLI1 This is the second major glioblastoma-specific aspirin mechanism. Acquired **temozolomide resistance** in glioma is often linked to abnormal **Sonic Hedgehog / GLI1** activation. Aspirin has been shown to inhibit this pathway and disrupt the **NF-κB–GLI1–ATM** loop that helps glioma cells survive DNA damage and repair double-strand breaks after temozolomide exposure. [Read the Aging paper](https://www.aging-us.com/article/101224/text) That matters because it is not just another anti-inflammatory effect. It is a resistance-pathway effect that fits the actual treatment pressure GBM patients face. In cell-line and mouse-model work, combining aspirin with **temozolomide** produced more tumour-cell death than either treatment alone. [Read the Aging paper](https://www.aging-us.com/article/101224/text) #### Angiogenesis inhibition and bevacizumab sensitisation GBM is one of the most vascular tumours in oncology. That makes angiogenesis central to survival and progression. Aspirin has shown anti-angiogenic effects in **glioblastoma endothelial cells** and has sensitised these cells to **temozolomide** and **bevacizumab** in preclinical models. [Read the paper](https://www.sciencedirect.com/science/article/abs/pii/S1878875018318631) This gives aspirin a plausible place in anti-vascular strategy, even though it remains unproven clinically. The broader angiogenesis relevance of GBM has been recognised for years. [Read the Lancet Neurology article](https://www.thelancet.com/journals/laneur/article/PIIS1474-4422\(04\)00758-6/fulltext) #### Wnt / β-catenin suppression Aspirin has also shown activity against **β-catenin / TCF** signalling in glioblastoma cell lines. In **U87** and **A172** models, it reduced β-catenin-driven transcription and lowered downstream targets such as **c-myc**, **Cyclin D1**, and **fra-1**. That was accompanied by lower proliferation, lower invasion, and more apoptosis. [Read the paper](https://pubmed.ncbi.nlm.nih.gov/21721879/) This is interesting because it links glioblastoma to one of aspirin's better-known pathway effects in gastrointestinal cancers, but now in a brain-tumour context. ### The blood-brain barrier problem This is the main reason aspirin is not already a meaningful glioblastoma drug discussion. Standard oral aspirin has limited ability to reach brain tissue at concentrations likely to reproduce the stronger laboratory effects. The **blood-brain barrier**, or **BBB**, remains the central delivery problem. [Read the coverage](https://www.sciencealert.com/scientists-think-they-ve-developed-a-drug-that-passes-the-blood-brain-barrier) That means the gap between mechanism and clinical use is larger here than in many other cancers. #### A potential formulation solution The most interesting attempt to solve this has been **IP1867B**, a soluble aspirin-based formulation designed to improve BBB penetration. Early laboratory reports suggested that this formulation was substantially more effective than standard treatment combinations in brain-tumour models and damaged tumour cells without the same injury to surrounding healthy tissue. [Read the Xtalks summary](https://xtalks.com/soluble-aspirin-for-glioblastoma-412/) This is still early-stage work. It is not Phase 3 evidence. But it does show that aspirin delivery into brain tumours is not being ignored. It is an active development problem. ### Clinical positioning | Setting | Evidence | Position | | --------------------------------------------------- | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | ------------------------------------------ | | **Glioma prevention** | Epidemiological signal with about **34%** lower risk and a duration pattern. [Read the coverage](https://www.livescience.com/54471-aspirin-linked-to-lower-brain-cancer-risk.html) | Supportive, but investigational | | **Brain-tumour mortality in long-term users** | Secondary-analysis signal with **HR 0.31** in the first 10 years. [Read the paper](https://pmc.ncbi.nlm.nih.gov/articles/PMC3619088/) | Interesting, but indirect | | **GBM stem-cell targeting** | Strong preclinical signal on **Notch1**, **Sox2**, **Stat3**, and **Survivin**. [Read the stem-cell paper](https://pubmed.ncbi.nlm.nih.gov/30701538/) | Strong mechanistic rationale | | **Temozolomide sensitisation** | Preclinical in vitro and in vivo support through **SHH / GLI1** suppression. [Read the Aging paper](https://www.aging-us.com/article/101224/text) | Directly relevant to resistant GBM biology | | **Bevacizumab sensitisation and anti-angiogenesis** | Preclinical endothelial-cell data. [Read the paper](https://www.sciencedirect.com/science/article/abs/pii/S1878875018318631) | Rational combination hypothesis | | **BBB-penetrant aspirin formulation** | Early laboratory-development work only. [Read the Xtalks summary](https://xtalks.com/soluble-aspirin-for-glioblastoma-412/) | Worth tracking, not clinically established | | **Standard oral aspirin as adjuvant therapy** | BBB limitation and no human GBM RCT | Not supported clinically | ### Why this matters despite being preclinical Glioblastoma is a disease where **standard survival remains poor** and recurrence remains the rule. That changes how preclinical evidence should be read. It does not lower the evidence bar. But it does make mechanistically rich work more worth tracking, especially when it targets the actual failure points of standard care. Aspirin is not interesting in GBM because it is cheap or familiar. It is interesting because it appears to hit: * **glioblastoma stem cells** * **temozolomide resistance** * **angiogenesis** * **Wnt / β-catenin** signalling * possibly **BBB-optimized formulation** development That is more mechanistic depth than many repurposed agents ever get in this disease. ### Practical interpretation This is not yet a page that supports routine aspirin use in people who already have glioblastoma. The most useful clinical questions are: 1. Is the discussion about **prevention epidemiology**, or about **post-diagnosis GBM biology**? 2. Is there interest in **temozolomide resistance**, **stem-cell persistence**, or **anti-angiogenic** strategy? 3. Is any aspirin discussion being confused with evidence for **standard oral aspirin**, when the real issue may be **brain delivery**? 4. Are there relevant **trial registers** or formulation programs, such as **IP1867B**, worth monitoring? That keeps the page evidence-based and avoids overselling a fascinating but still early field. ### References * 2019 stem-cell paper — aspirin targets glioblastoma stem cells and suppresses **Notch1**, **Sox2**, **Stat3**, and **Survivin**. [Read the paper](https://pubmed.ncbi.nlm.nih.gov/30701538/) * 2017 Aging paper — aspirin inhibits **SHH / GLI1** and sensitises glioma cells to **temozolomide**. [Read the paper](https://www.aging-us.com/article/101224/text) * 2018 angiogenesis paper — aspirin inhibits glioblastoma endothelial-cell angiogenesis and sensitises to **temozolomide** and **bevacizumab**. [Read the paper](https://www.sciencedirect.com/science/article/abs/pii/S1878875018318631) * 2011 β-catenin paper — aspirin suppresses **β-catenin / TCF** signalling in GBM models. [Read the paper](https://pubmed.ncbi.nlm.nih.gov/21721879/) * AACR 2016 epidemiology signal — regular aspirin use and lower glioma risk. [Read the coverage](https://www.livescience.com/54471-aspirin-linked-to-lower-brain-cancer-risk.html) * Secondary analysis of cardiovascular trials — lower primary-brain-tumour mortality in early long-term aspirin use. [Read the paper](https://pmc.ncbi.nlm.nih.gov/articles/PMC3619088/) * BBB and formulation coverage — aspirin delivery challenges and **IP1867B** development. [Read the coverage](https://www.sciencealert.com/scientists-think-they-ve-developed-a-drug-that-passes-the-blood-brain-barrier) * Early reporting on soluble aspirin formulation for glioblastoma. [Read the Xtalks summary](https://xtalks.com/soluble-aspirin-for-glioblastoma-412/) * Background angiogenesis context in glioblastoma. [Read the Lancet Neurology article](https://www.thelancet.com/journals/laneur/article/PIIS1474-4422\(04\)00758-6/fulltext)

Would you like to ask Abbey about the information shared on this page? Would you like to contribute your experience, research or ideas to this page? Perhaps you want to point out something that needs changing?

Feedback Form

{% hint style="warning" %} This information is for education only. It is not medical advice, diagnosis, or treatment. Please speak with a qualified clinician before making changes to care, medication, or supplement use. {% endhint %} {% hint style="info" %} © 2026 Abbey Mitchell. All rights reserved. Please share by URL rather than copying page text. {% endhint %} --- # Agent Instructions: Querying This Documentation If you need additional information that is not directly available in this page, you can query the documentation dynamically by asking a question. Perform an HTTP GET request on the current page URL with the `ask` query parameter: ``` GET https://myhealingcommunity.gitbook.io/myhealingcommunity-docs/off-label-drugs-for-cancer/aspirin-in-oncology/aspirin-evidence-by-cancer-type/glioblastoma.md?ask= ``` The question should be specific, self-contained, and written in natural language. The response will contain a direct answer to the question and relevant excerpts and sources from the documentation. Use this mechanism when the answer is not explicitly present in the current page, you need clarification or additional context, or you want to retrieve related documentation sections.